The hydroxy-methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer's risk and cognitive deterioration

[1]  B. Strooper,et al.  Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin , 2005, Nature Cell Biology.

[2]  David Posada,et al.  Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction , 2004 .

[3]  M. Endres,et al.  HMG‐CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis , 2004, Journal of neurochemistry.

[4]  L. Feuk,et al.  Variants of CYP46A1 may interact with age and APOE to influence CSF Aβ42 levels in Alzheimer’s disease , 2004, Human Genetics.

[5]  J. H. Boo,et al.  Lovastatin enhances Aβ production and senile plaque deposition in female Tg2576 mice , 2003, Neurobiology of Aging.

[6]  W. Maier,et al.  Association of the C766T polymorphism of the low‐density lipoprotein receptor‐related protein gene with Alzheimer's disease , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[7]  R. Nitsch,et al.  ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer’s disease , 2003, Neurobiology of Aging.

[8]  W. Noble,et al.  Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. , 2003, Brain research. Molecular brain research.

[9]  P. Chong,et al.  High-density lipoprotein cholesterol and the role of statins. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[10]  S. DeKosky,et al.  Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease , 2002, Neuroscience Letters.

[11]  Kenneth Rockwood,et al.  Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. , 2002, Archives of neurology.

[12]  B. Hyman,et al.  Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid β-peptide , 2001, Nature Cell Biology.

[13]  A. Ritchie,et al.  Polymorphism in the alpha1-antichymotrypsin (ACT) gene promoter: effect on expression in transfected glial and liver cell lines and plasma ACT concentrations , 2001, Human Genetics.

[14]  R. Doody,et al.  A method for estimating progression rates in Alzheimer disease. , 2001, Archives of neurology.

[15]  Rong Wang,et al.  Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model , 2000, Neurobiology of Disease.

[16]  G. Forloni,et al.  Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. , 2000, The Biochemical journal.

[17]  M. Franceschi,et al.  Association of early‐onset Alzheimer's disease with an interleukin‐1α gene polymorphism , 2000, Annals of neurology.

[18]  G. Annoni,et al.  Apolipoprotein E and α-1-antichymotrypsin allele polymorphism in sporadic and familial Alzheimer's disease , 1999, Neuroscience Letters.

[19]  D J Stephens,et al.  The role of cholesterol in the biosynthesis of beta-amyloid. , 1999, Neuroreport.

[20]  A. Koudinov,et al.  Alzheimer's amyloid beta and lipid metabolism: a missing link? , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  B. Greenberg,et al.  Modulation of Secreted β-Amyloid Precursor Protein and Amyloid β-Peptide in Brain by Cholesterol* , 1998, The Journal of Biological Chemistry.

[22]  B. Strooper,et al.  Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Rubinsztein.  The genetics of Alzheimer's disease , 1997, Progress in Neurobiology.

[24]  W. Klein,et al.  Cholesterol Modulates -Secretase Cleavage of Amyloid Precursor Protein (*) , 1996, The Journal of Biological Chemistry.

[25]  E M Wijsman,et al.  Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease , 1995, Neurology.

[26]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[27]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[28]  R. Mahley,et al.  Lipoprotein uptake by neuronal growth cones in vitro. , 1987, Science.

[29]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[30]  H. Braak,et al.  Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. , 2003, Archives of neurology.

[31]  B. Wolozin.  Cyp46 (24S-cholesterol hydroxylase): a genetic risk factor for Alzheimer disease. , 2003, Archives of neurology.

[32]  M. Tsolaki,et al.  Genetic association of acyl-coenzyme A: cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer's disease , 2003, Molecular Psychiatry.

[33]  P. Casey,et al.  Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.